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Gouty Arthritis
Erin Dutt, BSN, RN
Otterbein University, Westerville, Ohio
Significance of Underlying
Pathophysiology

Introduction
Gouty arthritis is a relatively common
diagnosis within the United States. It is
estimated that 9.2 million Americans
suffer from gout (Golenbiewski &
Keenan, 2019). Gouty arthritis is also
believed to be on the rise (Golenbiewski
& Keenan, 2019). This may correlate
with the aging baby boomer generation
since age is a risk factor. The rise of
conditions that increase the risk for
gouty arthritis is another correlation
(Harding, 2016). These conditions
include hypertension (HTN), type 2
diabetes mellitus, and chronic kidney
disease (Harding, 2016). It is very
probable that gouty arthritis will be
encountered within the primary care
setting. Gouty arthritis is a condition
that may be treated and managed in
primary care by a family nurse
practitioner (FNP). FNPs should be
knowledgeable of when to refer or
consult with rheumatology specialists.

Figure 1: MSU crystals
Credit: By Bobjgalindo - Own work, CC BY-SA 4.0,
https://commons.wikimedia.org/w/index.php?curid=5653456

Signs & Symptoms
•
•
•

Case Study
The following is a fictitious case study
that represents a scenario that could be
encountered in primary practice:
•
48-year-old male presents with
severe pain (“toe is on fire”
description) in his right big toe,
which is accompanied by
inflammation and erythema
•
Denies any fever, chills, or trauma
•
Current prescription regimen:
simvastatin 40 mg daily for
hyperlipidemia for 6 years and
hydrochlorothiazide 25 mg daily
for HTN for 5 years
•
Other factors include consistent
weight gain for the past 5 years; he
is about 50 pounds overweight
•
Social history includes drinking a
six-pack of beer daily
The remainder of this presentation will
provide the FNP with the knowledge and
tools on how to address and treat such a
case.

Common initial presentation is redness, swelling, and pain of the big
toe (Golenbiewski & Keenan, 2019)
Feet, ankle, hands, wrists, elbows may also be affected (Golenbiewski
& Keenan, 2019)
Associated symptoms: shiny skin, mild fever or chills, loss of appetite
(Golenbiewski & Keenan, 2019)

There are four stages to gouty arthritis: asymptomatic
tissue deposition, acute flares, inter-critical segments
(continued crystal deposition), and chronic gout
(American College of Rheumatology [ACR], 2019). Key
points to these phases include:
•
Asymptomatic hyperuricemia may be an incidental
finding and does not necessarily warrant treatment
for gout (Golenbiewski & Keenan, 2019)
•
SUA levels may be normal during an acute attack
and require obtaining a baseline after the attack
resolves (Harding, 2016)
•
In the inter-critical segment, crystals remain and
may require ongoing treatment for hyperuricemia
(Ragab et al., 2017).
•
Repeated acute flare ups lead to chronic gouty
arthritis. This leads to tissue destruction and
deformity caused by tophi which permanent
deposits of urate crystals along the joints (Ragab et
al., 2017).
•
Chronic gout leads to an increased risk for kidney
stones composed of urate and urate nephropathy
(Harding, 2016). Urate nephropathy is a buildup of
crystals in the kidney interstitium and tubules
leading to renal failure.

Implications for Nursing Care
•
•
•
•
•
•

Medications for Acute Gouty Arthritis (Hanier, Matheson, & Wilkes,
2014)
o
NSAIDs (first line of therapy)
o
Colchicine (no analgesic properties; should not be
administered after 36 hours of onset)
o
Corticosteroids (preferred for NSAIDs and colchicine
contraindication)
o
Do not initiate urate lowering therapy (ULT) during an
acute attack

•

Medications for Prevention of Chronic Gouty Arthritis (Hanier et al.,
2014)
o
Colchicine
o
Pegloticase
o
Xanthine oxidase inhibitors: Allopurinol, febuxostat

•

Dietary recommendations: reduction or avoidance of foods that can
increase SUA (Golenbiewski & Keenan, 2019):
o
Alcohol
o
Meats (organ, red and/or processed)
o
High fructose corn syrup

•

Risk factors (ACR, 2019):
o
Lifestyle and other factors:

Diet

Alcohol consumption

Male

Family history

Underlying Pathophysiology
Gout is a metabolic disorder that results in painful, sometimes debilitating,
arthritis (Harding, 2016). The cause of this condition is a buildup of uric acid
in the blood and synovial fluid (McCance & Huether, 2018). It is associated
with purine metabolism and kidney function. Purines and pyrimidines in the
body become converted to uric acid (McCance & Huether, 2018). One
enzyme that plays a role in the breakdown of uric acid is xandine oxidase
(Golenbiewski & Keenan, 2019). Uric acid is then filtered in the blood and
excreted in the urine. Uric acid has a limited solubility and the threshold of
uric acid is about 6.8 mg/dL (Ragab, Elshahly, & Barin, 2017). Uric acid loses
a proton at a pH of about 7.4 and then becomes a urate ion (Ragab et al.,
2017). The urate ion binds sodium and forms monosodium urate crystals
(MSU) (McCance & Huether, 2018). MSU crystals are then deposited around
the joints (McCance & Huether, 2018). MSU crystals that are in the joint
cavity initiate the inflammatory process(Golenbiewski & Keenan, 2019).
Leukocytes will migrate to the affected site to release inflammatory
chemicals such as cytokines (Golenbiewski & Keenan, 2019). Acute attacks
are generally self-limited as mast cells help end the inflammatory period by
engulfing debris and crystals (Raga et al. 2017).
Hyperuricemia can occur if there is decreased or overproduction of uric acid.
Renal failure, HTN, and diuretics can lead to decreased excretion of uric acid
(Berkowitz, 2007). Causes of overproduction of uric acid include an
overconsumption of purines in meats and alcohol, increased cellular turnover
(hemolytic anemias or malignancies), and hypoxanthine guanine
phosphoribosyltransferase (HGPRT) deficiency (Lesch-Nyhan syndrome)
which is an inherited X-linked disorder (Berkowitz, 2007). 90% of cases are
caused by renal underexcretion (Ragab, et al, 2017).

Tophus of the knee

Diagnosis can only be confirmed by identifying MSU crystals within
synovial fluid (Ragab et al., 2017)
Normal SUA levels are 3.5-7.2 mg/dL (ACR, 2019)
Target SUA is <6 mg/dL (ACR, 2019)
Treatment is aimed at lowering urate levels and making dietary
changes. Management of acute flares are aimed at managing
inflammation and restoring function (Golenbiewski & Keenan, 2019).
Not all respond to ULT and have refractory gout

o

o
Figure 2: By NickGorton - NickGorton, CC BY 2.5,
https://commons.wikimedia.org/w/index.php?curid=1
324804

Health conditions:

HTN

Obesity

Hyperthyroidism

Renal insufficiency

Hemolytic anemia

Kelley-Seegmiller syndrome

Lesch-Nyhan syndrome
Medications:






Diuretics
Salicylate containing drugs
Niacin
Cyclosporine
Levodopa

Hyperuricemia
Management

Figure 3: Credit: Harding, 2016

Revisit the Case Study
Within the case study and the information provided,
it would be reasonable for the FNP to suspect an
acute gout attack. His age, sex, location/description
of pain, inflammation of the big toe, history of HTN,
prescription of the diuretic HCTZ, increased weight,
and alcohol use are all factors that influence the
development of gout. The acute attack should be
managed with appropriate pharmacologic therapy.
Changing the HCTZ to another option to manage
HTN should be considered. A referral to a
rheumatologist is appropriate to identify MSU
crystals within the joint and to determine the longterm plan. Patient education regarding diet, weight,
and alcohol use will be vital to help prevent future
attacks and joint damage.

Conclusion
Though gout is well understood, it
generally remains poorly managed.
The keys reasons for this are poor
diet, widespread use of diuretics,
comorbidities such obesity and HTN
(Mead, Arabindoo, & Smith, 2014).
Studies show that less than half of
patients on urate lowering therapy
are compliant with medication (Mead
et al., 2014). To help combat this
issue, providers can increase followup appointments (Mead et al., 2014).
Acute flares are aimed at managing
inflammation and restoring function
(Golenbiewski & Keenan, 2019). Once
the acute attack subsides, treatment
is aimed at lowering urate levels and
making dietary changes. If noncompliance is not thought to be an
issue and the patient is not
responding to treatment, refractory
gout may need to be considered and
treated accordingly. Finally, it is
important for the FNP to note that
guidelines for treatment may change
in the future. Current ACR guidelines
were published in 2012. These
guidelines are currently under review
and updated recommendations can
be expected in 2020 (ACR, 2019).
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